EcoDrugPlus

Phospholipase A2-Like

Ensembl ID : ENSAOCG00000003831
Gene Symbol: LOC111576712
3 Cross references
233 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSAOCG00000002838
Gene Symbol: GART
3 Cross references
212 Possible Orthologues:

Plasminogen

Ensembl ID : ENSAOCG00000007117
Gene Symbol: PLG
3 Cross references
256 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSAOCG00000003161
Gene Symbol: PLAT
3 Cross references
207 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSAOCG00000001118
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSAOCG00000005156
Gene Symbol: PDGFRA
3 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSAOCG00000000405
Gene Symbol: PDGFRB
3 Cross references
199 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSAOCG00000015874
Gene Symbol: LOC111575719
2 Cross references
174 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSAOCG00000022832
Gene Symbol: PLK1
4 Cross references
187 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSAOCG00000006564
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSAOCG00000021005
Gene Symbol: PARP1
3 Cross references
209 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSAOCG00000007473
Gene Symbol: PARP2
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).